GlassScriptPhysician profile
Nathan Robert Peterson
NPI 1194135350
$2,775.07
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $737 · 2021: $205 · 2022: $12.44 · 2023: $99.99 · 2024: $20.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $20.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $20.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $324.78 | 2019-2021 | |
| Pfizer INC. | $216.02 | 2019-2020 | |
| Lilly USA, LLC | $200.77 | 2019-2020 | |
| Celgene Corporation | $198.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Seagen INC. | $148.16 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $139.27 | 2019-2020 | |
| Amgen INC. | $132.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $132.67 | 2020-2021 | |
| Janssen Biotech, INC. | $124.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $121.82 | 2019-2020 | |
| Gilead Sciences, INC. | $111.91 | 2021-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $107.92 | 2019-2021 | |
| Incyte Corporation | $105.05 | 2019-2020 | |
| Daiichi Sankyo INC. | $96.32 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $71.42 | 2019-2020 | |
| Foundation Medicine, INC. | $43.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.69 | 2020-2021 | |
| Taiho Oncology, INC. | $39.86 | 2019 | |
| Genentech USA, INC. | $38.18 | 2019 | |
| Abbvie INC. | $36.81 | 2020-2024 | |
| Tesaro, INC. | $35.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.93 | 2019 | |
| Dova Pharmaceuticals | $23.49 | 2019 | |
| Kite Pharma, INC. | $18.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.46 | 2019 | |
| Secura Bio, INC. | $17.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.25 | 2019 | |
| Merck Sharp & Dohme LLC | $12.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.